Dillinger JG
France
Research Article
Glycoprotein Iib/Iiia Inhibitors in Acute ST-Segment Elevation Myocardial Infarction: Evaluation of Clinical Practice and Cost/Efficacy Analysis
Author(s): Cuny P, Benmiloud S, Oliary J, Dillinger JG, Sideris G, Henry P and Manzo-Silberman S*
Cuny P, Benmiloud S, Oliary J, Dillinger JG, Sideris G, Henry P and Manzo-Silberman S*
Associated to primary percutaneous coronary intervention (pPCI), pharmacotherapy in acute ST-Segment elevation myocardial infarction (STEMI) patients have transformed the management of the acute phase. Use of glycoprotein IIb/IIIa inhibitors (GPI) remains debatable, level of guidelines has been modified in the successive editions of guidelines. In the latest European Society of Cardiology guidelines, GPI have a IIb B level in upstream use and IIa C in bail out during pPCI procedure. In front of the varying recommendations, we analysed clinical characteristics of patients with ST-Segment elevation myocardial infarction according to the use of GPI. We evaluate complications during hospitalization, particularly bleeding events. The cost of patients’ management was also analysed.
We conducted a retrospective, descriptive and monocentric study from January 2010 to December .. View More»
DOI:
10.4172/2329-6607.1000236